KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Morbidity and quality of life of totally laparoscopic versus laparoscopy-assisted distal gastrectomy for early gastric cancer: a multi-center prospective randomized controlled trial (CKLASS01).Gastric CancerPMID 39499377无 PMCID2025-Jan0.93干预为非药物单独策略,未满足药物干预要求。待处理
Long-term reductions in acute headache medication use after eptinezumab treatment in patients with migraine and prior preventive treatment failures: Post hoc analysis of the DELIVER randomized trial.HeadachePMID 39501727PMC117260112025-Jan0.98未发现恶性肿瘤人群证据。待处理
Impact of cytopenias and early versus late treatment with ruxolitinib in patients with steroid-refractory acute or chronic graft-versus-host disease.Bone Marrow TransplantPMID 39506073PMC117264462025-Jan0.98未发现恶性肿瘤人群证据。待处理
Protocol compliance in a multicentric phase III trial investigating scheduled adaptive radiotherapy and dose painting in head and neck cancer.Radiother OncolPMID 39522824无 PMCID2025-Jan0.90The record describes a Phase III randomized trial in human oncology (head and neck cancer) with a time-to-event primary endpoint (locoregional control). However, the abstract focuses on quality assurance and protocol adherence analysis of the radiotherapy intervention, not on the formal efficacy results of a drug-containing intervention. No drug intervention is mentioned; the trial investigates scheduled adaptive radiotherapy and dose painting. While the primary endpoint is time-to-event, the abstract does not report Kaplan-Meier curves, hazard ratios, or other time-to-event efficacy results; it reports on the impact of protocol deviations. Therefore, it does not meet the criteria for inclusion in a KM digitization cohort requiring a drug intervention and formal time-to-event efficacy results.待处理
Optimum radiation dose for palliation in head and neck squamous cell carcinoma (OpRAH) - A phase 3 randomized controlled trial.Radiother Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39522825无 PMCID2025-Jan0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).Gynecol Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39531903无 PMCID2025-Jan0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Efficacy and Safety Analysis in Chinese Patients with Moderate-to-Severe Psoriasis from a Phase 3 Trial: Impact of Treatment Withdrawal and Retreatment of Ixekizumab.Adv TherPMID 39535685PMC117823302025-Jan0.98未发现恶性肿瘤人群证据。待处理
Ruxolitinib Cream Monotherapy Improved Symptoms and Quality of Life in Adults and Adolescents with Mild-to-Moderate Atopic Dermatitis: Patient-Reported Outcomes from Two Phase III Studies.Am J Clin DermatolPMID 39546129PMC117424602025-Jan0.98未发现恶性肿瘤人群证据。待处理
A randomised, placebo-controlled, phase III trial of leniolisib in activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS): Adolescent and adult subgroup analysis.Clin ImmunolPMID 39561927PMC116316592025-Jan0.98未发现恶性肿瘤人群证据。待处理
Thyroidectomy without radioiodine in patients with low-risk thyroid cancer: 5 years of follow-up of the prospective randomised ESTIMABL2 trial.Lancet Diabetes EndocrinolPMID 39586309无 PMCID2025-Jan0.85The study is an oncology phase 3 randomized trial with original results, but it is excluded because the intervention is radioiodine (a radioisotope, not a drug) and the primary endpoint is not a standard time-to-event efficacy endpoint (OS, PFS, DFS, etc.) with Kaplan-Meier or HR analysis.待处理
Efficacy and Safety of a Dedicated Device for Cerebral Venous Thrombectomy: A Pilot Randomized Clinical Trial.StrokePMID 39601121无 PMCID2025-Jan0.98未发现恶性肿瘤人群证据。待处理
De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial.Lancet OncolPMID 39612919无 PMCID2025-Jan0.95The study is a Phase III randomized trial in oncology with drug interventions and reports final results for its primary endpoint. However, the primary endpoint is pathological complete response (pCR), which is a binary efficacy measure, not a time-to-event endpoint such as overall survival or progression-free survival. Therefore, it does not meet the core criterion of having a primary/key secondary time-to-event efficacy endpoint.待处理
Impact of HA-PCI on self-reported cognitive functioning and brain metastases in small-cell lung cancer: Pooled findings of NCT01780675 and PREMER trials.Lung CancerPMID 39615412无 PMCID2025-Jan0.90The record describes a randomized Phase III trial comparing two radiation techniques (PCI vs. HA-PCI) for a time-to-event endpoint (brain metastases). While it meets criteria for oncology, human, randomized, phase, and time-to-event, it fails the mandatory drug intervention criterion, as the intervention is purely a non-drug radiotherapy technique.待处理
Safety and efficacy of intravenous recombinant human prourokinase for acute ischaemic stroke within 4·5 h after stroke onset (PROST-2): a phase 3, open-label, non-inferiority, randomised controlled trial.Lancet NeurolPMID 39617030无 PMCID2025-Jan0.98未发现恶性肿瘤人群证据。待处理
Dupilumab improves sense of smell and clinical outcomes in patients with severe chronic rhinosinusitis with nasal polyps with anosmia.Curr Med Res OpinPMID 39618256无 PMCID2025-Jan0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of lebrikizumab combined with topical corticosteroids in Japanese patients with moderate-to-severe atopic dermatitis: a phase 3, double-blind, placebo-controlled, randomized clinical trial (ADhere-J).Curr Med Res OpinPMID 39625230无 PMCID2025-Jan0.98未发现恶性肿瘤人群证据。待处理
Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial.Lancet HaematolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 39642900无 PMCID2025-Jan0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trial.Lancet HaematolPMID 39644907无 PMCID2025-Jan0.98未发现恶性肿瘤人群证据。待处理
Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial.Gynecol Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39657575无 PMCID2025-Jan0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。无 KM 图
Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trial.Lancet OncolPMID 39675376无 PMCID2025-Jan0.95The report is a phase 3 randomized trial in oncology with a drug intervention, but the presented results focus on a quality-of-life endpoint (GHS) at 24 months. The time-to-event efficacy endpoint (ipsilateral breast tumour recurrence) is a co-primary endpoint but is explicitly noted as 'not reported here'. Therefore, it does not meet the criterion for a primary/key secondary time-to-event efficacy endpoint.待处理
Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD).J Alzheimers DisPMID 39686620无 PMCID2025-Jan0.98未发现恶性肿瘤人群证据。待处理
Long-term follow-up of patients with a first clinical demyelinating event (clinically isolated syndrome) who received cladribine tablets in CLASSIC-MS: Findings for the ORACLE-MS cohort.Mult SclerPMID 39690897无 PMCID2025-Jan0.98未发现恶性肿瘤人群证据。待处理
An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-2016.Lung Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39700681无 PMCID2025-Jan0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Multivariable prognostic prediction of efficacy and safety outcomes and response to fingolimod in people with relapsing-remitting multiple sclerosis.Mult Scler Relat DisordPMID 39733600无 PMCID2025-Jan0.80The study is a secondary analysis/prognostic model development using data from two Phase II/III RCTs of fingolimod in Multiple Sclerosis. While it involves a drug, randomized trials, and time-to-event analysis (Cox models for relapse), it is not an oncology study. Furthermore, it is not the primary formal report of the original trial results but rather a subsequent analysis aiming to predict individual treatment response. Therefore, it does not meet the core criteria for inclusion in an oncology Kaplan-Meier digitization cohort.待处理
Phase 3 Study of Talazoparib Plus Enzalutamide Versus Placebo Plus Enzalutamide as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer: TALAPRO-2 Japanese Subgroup Analysis.Cancer MedPMID 39737542PMC116863352025-Jan0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。已完成
A Five-Year Prospective, Randomized, Open-Label Study of Standard-Dose Versus Low-Dose Prolonged-Release Tacrolimus With or Without Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker Post Kidney Transplantation.Clin Transplant疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:非 KM 图。PMID 39739990PMC116838582025-Jan0.98未发现恶性肿瘤人群证据。无 KM 图
Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patients.ESMO OpenPMID 39754976PMC117581242025-Jan0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial.Lancet HaematolPMID 39756844PMC123212452025-Jan0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Opicapone as adjunct to levodopa in treated Parkinson's disease without motor complications: A randomized clinical trial.Eur J NeurolPMID 39790009PMC117182182025-Jan0.98未发现恶性肿瘤人群证据。待处理
Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial.J Prev Alzheimers DisPMID 39800452PMC121840162025-Jan0.98未发现恶性肿瘤人群证据。待处理
Efficacy and Safety of Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled by Amlodipine: A Phase III, Multicenter, Double-Blind, Parallel-Group, Randomized Controlled Trial.J Clin Hypertens (Greenwich)PMID 39821945PMC117717832025-Jan0.98未发现恶性肿瘤人群证据。待处理
Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria.Ann HematolPMID 39841198PMC118682142025-Jan0.98未发现恶性肿瘤人群证据。已完成
Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2-Low, Hormone Receptor-Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical Trials.JCO Precis OncolPMID 39854658PMC118355112025-Jan0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers During Prescreening for the Phase III FORTITUDE-101 Trial.JCO Precis OncolPMID 39854659PMC117815612025-Jan0.85The record describes a prescreening prevalence study of FGFR2b overexpression for a Phase III trial. While it is linked to a definitive randomized controlled oncology trial, it does not report the required survival or efficacy outcomes (e.g., OS, PFS, ORR, death, hazard ratios). It is a secondary/biomarker analysis report focused on prevalence, not trial efficacy.待处理
Digital Pathology-Based Multimodal Artificial Intelligence Scores and Outcomes in a Randomized Phase III Trial in Men With Nonmetastatic Castration-Resistant Prostate Cancer.JCO Precis OncolPMID 39889245无 PMCID2025-Jan0.95This is a post-hoc subgroup/biomarker analysis (digital pathology-based AI) of the primary SPARTAN trial. While it reports time-to-event outcomes for a drug-containing arm, it is not the original primary efficacy report of the randomized trial, but an exploratory biomarker study within it.待处理
Long-Term Efficacy and Safety of Damoctocog Alfa Pegol Prophylaxis in Patients with Haemophilia A Aged 12-<18 Years at Enrolment into PROTECT VIII.Acta HaematolPMID 38599195PMC1180945420250.98未发现恶性肿瘤人群证据。待处理
Efficacy, Safety, and Quality of Life of Pegcetacoplan in Japanese Patients with Paroxysmal Nocturnal Hemoglobinuria Treated within the Phase 3 PEGASUS Trial.Acta HaematolPMID 38615657PMC1172350320250.98未发现恶性肿瘤人群证据。待处理
Effect of Cerebral Oximetry-Guided Treatment on Brain Injury in Preterm Infants as Assessed by Magnetic Resonance Imaging at Term Equivalent Age: An Ancillary SafeBoosC-III Study.NeonatologyPMID 38934161无 PMCID20250.98未发现恶性肿瘤人群证据。待处理
Centralized Quality Assurance of Stereotactic Body Radiation Therapy for the Veterans Affairs Cooperative Studies Program Study Number 2005: A Phase 3 Randomized Trial of Lung Cancer Surgery or Stereotactic Radiotherapy for Operable Early-Stage Non-Small Cell Lung Cancer (VALOR).Pract Radiat OncolPMID 39233006无 PMCID20250.85While the underlying trial is a Phase III randomized oncology trial, this specific publication is a quality assurance report for the SBRT component. It does not present primary or secondary efficacy results based on a time-to-event endpoint (OS, PFS, etc.). Furthermore, the intervention reported here (SBRT) is non-drug.待处理
Efficacy and Safety of Etrasimod in Patients with Ulcerative Colitis in Japan: Data from the Phase 3 ELEVATE UC 12 and ELEVATE UC 40 JAPAN Trials.DigestionPMID 39317165PMC1212941920250.98未发现恶性肿瘤人群证据。待处理
Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of Azelastine Hydrochloride in Children with Perennial Allergic Rhinitis.Int Arch Allergy ImmunolPMID 39647474PMC1216980320250.98未发现恶性肿瘤人群证据。待处理
Tenapanor Improves Abdominal Symptoms Irrespective of Changes in Complete Spontaneous Bowel Movement Frequency in Adults with Irritable Bowel Syndrome with Constipation.Dig DisPMID 39701047PMC1196583920250.98未发现恶性肿瘤人群证据。待处理
Efficacy, durability and safety of faricimab for patients with neovascular age-related macular degeneration: 48-week results from the phase 3 LUCERNE China subpopulation.Asia Pac J Ophthalmol (Phila)PMID 39818248无 PMCID20250.98未发现恶性肿瘤人群证据。待处理
Ensifentrine in COPD patients taking long-acting bronchodilators: A pooled post-hoc analysis of the ENHANCE-1/2 studies.Chron Respir DisPMID 39854278PMC1176012820250.98未发现恶性肿瘤人群证据。待处理
Dupilumab is efficacious for eosinophilic esophagitis irrespective of prior swallowed budesonide or fluticasone, or prior treatments used alongside swallowed topical corticosteroids: results from the phase 3, randomized, placebo-controlled, LIBERTY EoE TREET trial.Expert Rev Gastroenterol HepatolPMID 39909733无 PMCID20250.98未发现恶性肿瘤人群证据。待处理
Efficacy and Safety of GutGard® in Managing Gastroesophageal Reflux-Related Symptoms: A Phase III, Single-Centre, Double-Blind, Randomized Placebo-Controlled Trial.Complement Med ResPMID 39929150PMC1189246420250.98未发现恶性肿瘤人群证据。待处理
Vortioxetine versus SSRI/SNRI with Pregabalin Augmentation in Treatment-Resistant Burning Mouth Syndrome: A Prospective Clinical Trial.Curr NeuropharmacolPMID 40016875PMC1216346620250.98未发现恶性肿瘤人群证据。待处理
Effect of honey-ginger mouthwash on oral mucositis in patients undergoing chemotherapy.J Immunoassay ImmunochemPMID 40134126无 PMCID20250.95The study fails two key eligibility criteria for the specified cohort: (1) the intervention is not a systemic anticancer drug, and (2) the primary endpoint is not a time-to-event efficacy endpoint. While it is an oncology RCT with human subjects, a Phase III label, and reports primary results, it does not meet the core requirements for inclusion in a Kaplan-Meier digitization cohort focused on drug interventions and survival/time-to-event outcomes.待处理
Treatment of Plaque Psoriasis with Guselkumab Reduces Systemic Inflammatory Burden as Measured by Neutrophil/Lymphocyte Ratio, Platelet/Lymphocyte Ratio, and Monocyte/Lymphocyte Ratio: A post hoc Analysis of Three Randomised Clinical Trials.DermatologyPMID 40209685PMC1214384820250.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
CONKO-011/AIO-SUP-0115/ass.: Rivaroxaban Compared to Low Molecular Weight Heparin in Cancer Patients with Acute Venous Thromboembolism.Oncol Res TreatPMID 40418924PMC1223728120250.95The study is an oncology randomized Phase III trial with a drug intervention, but it does not have a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, or analysis using Kaplan-Meier/HR). The primary endpoint is patient-reported treatment satisfaction, and secondary endpoints include recurrent VTE and mortality, but the reported results are based on scale scores and proportions, not time-to-event analysis.待处理